DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The Effects of Antihypertensive Agents on Central Blood Pressure in Healthy Participants and Participants With Hypertension (MK-0000-166) (COMPLETED)

Information source: Merck Sharp & Dohme Corp.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Placebo (Drug); Comparator: Amlodipine (Drug); Comparator: ISMN ER (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Merck Sharp & Dohme Corp.

Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Merck Sharp & Dohme Corp.

Summary

This study will test the relationship between CBP (central blood pressure) and PBP (peripheral blood pressure) effects after single and multiple doses of Isosorbide mononitrate extended release (ISMN ER) or Amlodipine besylate in participants with hypertension.

Clinical Details

Official title: A Double-Blind, Randomized, Placebo-Controlled, 3-Period, Crossover Study to Evaluate the Effects of Antihypertensive Agents on Central Blood Pressure in Healthy Subjects and Patients With Hypertension

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome:

Time-weighted Average (TWA) Change From Baseline (0 Hours) to 12 Hours in Heart-Rate-Corrected Augmentation Index (AIx) After A Single Dose of Treatment

Change From Baseline (0 Hours) to Week 4 in Heart-Rate-Corrected AIx After Multiple Doses of Treatment

TWA Change From Baseline (0 Hours) to 12 Hours in Central Systolic Blood Pressure (SBP) After A Single Dose of Treatment

Change From Baseline (0 Hours) to Week 4 in Central SBP After Multiple Doses of Treatment

TWA Change From Baseline (0 Hours) to 12 Hours in Central Diastolic Blood Pressure (DBP) After A Single Dose of Treatment

Change From Baseline (0 Hours) to Week 4 in Central DBP After Multiple Doses of Treatment

TWA Change From Baseline (0 Hours) to 12 Hours in Peripheral SBP After A Single Dose of Treatment

Change From Baseline (0 Hours) to Week 4 in Peripheral SBP After Multiple Doses of Treatment

TWA Change From Baseline (0 Hours) to 12 Hours in Peripheral DBP After A Single Dose of Treatment

Change From Baseline (0 Hours) to Week 4 in Peripheral DBP After Multiple Doses of Treatment

Eligibility

Minimum age: 30 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Participant is a male or female between 30 and 65 years of age (inclusive) at the

pre-study (screening)

- Female participant of childbearing potential must have a negative pregnancy test

- Participant has a brachial systolic blood pressure >130 mm Hg

and <180 mm Hg

- Participant has a Body Mass Index (BMI) that is >20 kg/m^2 and <35 kg/m^2

- Participant has been a nonsmoker and/or has not used nicotine or nicotine-containing

products for at least approximately 6 months Exclusion Criteria:

- Female Participant is pregnant or lactating

- Participant anticipates the use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

other than acetaminophen

- Participant is currently a user (including "recreational use") of any illicit drugs,

has a history of drug or alcohol abuse within approximately 2 years, or has a positive prestudy urine drug screen

- Participant has a condition for which there is a warning, contraindication, or

precaution against the use of ISMN ER including: acute myocardial infarction or congestive heart failure, hypotension, volume depletion, and pregnancy

- Participant has a history of significant drug allergy or any clinically significant

adverse experience of a serious nature related to the administration of either a marketed or an investigational drug, including nitrates, nitrites, Amlodipine, and ISMN ER

Locations and Contacts

Additional Information

Starting date: May 2010
Last updated: April 21, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017